Analysts forecast that Transenterix Inc (NYSE:TRXC) will post sales of $110,000.00 for the current quarter, according to Zacks. Two analysts have issued estimates for Transenterix’s earnings, with the lowest sales estimate coming in at $60,000.00 and the highest estimate coming in at $150,000.00. Transenterix posted sales of ($999,000,000.00) in the same quarter last year, which suggests a positive year-over-year growth rate of 100%. The company is scheduled to report its next quarterly earnings results on Friday, August 4th.

On average, analysts expect that Transenterix will report full-year sales of $110,000.00 for the current year, with estimates ranging from $6.26 million to $8.6 million. For the next fiscal year, analysts expect that the business will post sales of $33.66 million per share, with estimates ranging from $16.6 million to $49.9 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Transenterix.

Transenterix (NYSE:TRXC) last posted its quarterly earnings results on Monday, March 6th. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.01.

A number of equities analysts have recently weighed in on the stock. B. Riley reaffirmed a “buy” rating and issued a $2.75 price target on shares of Transenterix in a research note on Tuesday, March 7th. Raymond James Financial, Inc. downgraded shares of Transenterix from an “outperform” rating to a “mkt perform” rating in a research report on Thursday, January 19th. Finally, Zacks Investment Research raised shares of Transenterix from a “sell” rating to a “hold” rating in a research report on Tuesday, January 24th.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/05/19/110000-00-in-sales-expected-for-transenterix-inc-trxc-this-quarter.html.

Shares of Transenterix (NYSE:TRXC) traded down 0.0182% on Friday, hitting $0.5503. The company’s stock had a trading volume of 858,448 shares. The stock’s 50 day moving average price is $0.88 and its 200 day moving average price is $1.27. The stock’s market capitalization is $81.74 million. Transenterix has a 52 week low of $0.52 and a 52 week high of $2.33.

A hedge fund recently raised its stake in Transenterix stock. State Street Corp raised its stake in shares of Transenterix Inc (NYSE:TRXC) by 14.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 849,678 shares of the medical instruments supplier’s stock after buying an additional 106,040 shares during the period. State Street Corp owned 0.74% of Transenterix worth $1,104,000 as of its most recent SEC filing.

About Transenterix

TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.

5 Day Chart for NYSE:TRXC

Get a free copy of the Zacks research report on Transenterix (TRXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.